Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.30 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Steady growth and dividend increases over decades can make investors remarkably wealthy. 
Via The Motley Fool
Topics Economy
Exposures Economy
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment. 
Via Investor's Business Daily
2 Weight Loss Drug Stocks That Are Screaming Buys in June
These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings. 
Via The Motley Fool
Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading
A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks. 
Via Benzinga
Vaccine Stocks Alert: Has RFK Jr.'s CDC Panel Shakeup Sent Retail Traders To The Sidelines?
Kennedy said the Department of Health and Human Services would retire all 17 current members of the ACIP, citing what he called a "crisis of public trust." 
Via Stocktwits
Topics Government
Exposures COVID-19 Political
Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr.
A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition. 
Via Investor's Business Daily
Topics Government
Exposures COVID-19 Political
Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes
The company said that the drug, MET-233i, demonstrated up to 8.4% mean placebo-subtracted weight loss at day 36. 
Via Stocktwits
Topics Government
Exposures Political
These S&P500 stocks are the most active in today's session
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest. 
Via Chartmill
Pfizer CEO Reportedly Says Company Made No Drug Price Pledges In Meeting With Trump Administration: Retail Sentiment Improves
The meeting follows an executive order from President Trump last month, which directed drugmakers to lower medicine prices to the levels paid by other high-income countries. 
Via Stocktwits
Topics Artificial Intelligence Government
Exposures Artificial Intelligence COVID-19 Political
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Should You Buy Pfizer Stock Right Now?
Via The Motley Fool
Exposures COVID-19
Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval
Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients 
Via Benzinga
Exposures Product Safety
RFK Jr. Champions 'Medical Freedom' While Curtailing Access, Say Public Health Experts
U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health... 
Via Benzinga
Exposures COVID-19
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
Via The Motley Fool
Topics Intellectual Property Retirement
Exposures COVID-19 Intellectual Property Pension
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
A volatile stock market represents an ideal opportunity for long-term investors to pounce. 
Via The Motley Fool
Topics Stocks
Exposures COVID-19 US Equities
Hundreds Sue Pfizer Over Birth Control Jabs Linked to Brain Tumors
Via Investor Brand Network
Topics Lawsuit
Exposures Financial Legal
S&P 500 Earnings Stun The Street In Q1 With Broad-Based Beats, Double-Digit Growth
Nearly 80% of S&P 500 firms beat Q1 earnings forecasts. Profit growth hit 13.3%, led by tech and health care, says FactSet. 
Via Benzinga
Topics Stocks
Exposures US Equities
These 2 Dow Stocks Are Set to Soar in 2025 and Beyond
Apple and Cisco could generate surprising gains over the next few years. 
Via The Motley Fool
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence COVID-19 Economy
3 Safe Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 11.35% -- That Make for No-Brainer Buys in June
Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond. 
Via The Motley Fool
Why BioNTech Stock Soared Today
Bristol Myers Squibb just agreed to shower BioNTech with cash. 
Via The Motley Fool
Exposures COVID-19
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Michael McTague: Watch out for these killer superbugs that resist today’s antibiotics
These mutated diseases defy the power of antibiotics. Are illnesses really mutating so fast that we can’t stay ahead of them? It appears that these devils 
Via Equities.com
Topics Death
Exposures Death
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer (NYSE:PFE) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Terrible News for Pfizer Stock Investors
Via The Motley Fool
Exposures COVID-19 Product Safety
Beat the S&P 500 With This Cash-Gushing Dividend Stock
The business may be somewhat boring, but it consistently delivers year after year, resulting in tremendous long-term returns. 
Via The Motley Fool
Topics Artificial Intelligence Bonds Intellectual Property
Exposures Artificial Intelligence Debt Markets Intellectual Property
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%
Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 trial. 
Via Benzinga
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.